Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cervarix: Two Years Late, But In for the Duration

This article was originally published in RPM Report

Executive Summary

GlaxoSmithKline has encountered numerous hurdles trying to get its HPV vaccine onto the market to compete in the US against Merck’s Gardasil. GSK appears fi nally on the verge of completing the long process. The question for GSK—and the rest of the vaccine business—is whether the company has created the case for a strong product differentiation for Cervarix versus Gardasil. If it has, it will trigger a new era of vaccine marketing and product development.
Advertisement

Related Content

The Vaccines Trust Gap: From Miracle to Menace and Back Again
Halo Effect: Pandemic Response, Vaccines and Public Health
Novartis Bets Big on Meningitis:Wall Street Awaits Blockbuster Vaccine Franchise
Cervarix Delayed: Setback for GSK is Opportunity for FDA to Create New Model for Adjuvant Approvals
Vaccines Enter the New Age of Adjuvants
Vaccines Enter the New Age of Adjuvants

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS080613

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel